The control group scored a mean of 7.5 out of 10, while the cases averaged 7.0, a statistically significant difference (P=0.046) even when adjusting for diabetes status
10.1016/j.cell.2011.02.013 2
Public Health Recommendations The CPHA article outlines three recommendations for the public health sector: Addressing industry influence and the commercial determinants of health, including engagement in policy reform around drug pricing, regulation, and access [Source: cpha.ca/glp-1-agonists-and-obesity-public-health-perspective] Strengthening evidence and surveillance to track GLP-1 use, access, outcomes, and inequities [Source: cpha.ca/glp-1-agonists-and-obesity-public-health-perspective] Countering misinformation through knowledge translation and health education initiatives [Source: cpha.ca/glp-1-agonists-and-obesity-public-health-perspective] The author writes that long-term effectiveness of GLP-1 drugs in everyday use remains uncertain, including whether changes are sustained and what happens after stopping treatment [Source: cpha.ca/glp-1-agonists-and-obesity-public-health-perspective]
All timelines are extrapolated from animal research and community reports
Over time, repeated oxidative injury promotes endothelial apoptosis and maladaptive repair responses, including smooth muscle proliferation and vascular calcification